Navidea articles & resources on Made-in-China.com

Navidea Biopharmaceuticals Has Submitted a Supplemental New Drug Application

Dec 19, 2013

Navidea Biopharmaceuticals has submitted a supplemental new drug application (sNDA) to the US Food and Drug Administration (FDA) for the approval to market and sale Lymphoseek Injection for sentinel lymph node (SLN) detection in patients ...

Tags: Health, Medicine

Navidea Biopharmaceuticals Will Collaborate with The UAB on a Clinical Study

Nov 29, 2013

Navidea Biopharmaceuticals will collaborate with the University of Alabama at Birmingham (UAB) on a clinical study that will assess the safety and activity of a radiolabeled, humanized monoclonal antibody from its RIGS (radio-immuno-guided ...

Tags: Health, Medicine

The US FDA Had Approved Lymphoseek Injection in March 2013

May 6, 2013

Navidea Biopharmaceuticals has launched its Lymphoseek (technetium Tc 99m tilmanocept) Injection in the US. The injection is used in lymphatic mapping procedures that help in the diagnostic evaluation of potential cancer spread for ...

Tags: Navidea, Lymphoseek

FDA Has Approved Navidea Biopharmaceuticals' Lymphoseek Injection

Mar 15, 2013

The US Food and Drug Administration (FDA) has approved Navidea Biopharmaceuticals' Lymphoseek (technetium Tc 99m tilmanocept) injection, a novel product indicated for use in lymphatic mapping procedure. The lymphatic mapping procedure ...

Tags: FDA, Biopharmaceuticals, Navidea Biopharma

Navidea Collaborate with Maimonides Medical Center to Find The Use of Lymphoseek Injection

Feb 13, 2013

Navidea Biopharmaceuticals has collaborated with Maimonides Medical Center to find the use of Lymphoseek (technetium Tc 99m tilmanocept) injection for lymphatic mapping in colorectal cancer. The investigator-initiated study will be ...

Tags: Navidea, Medical Center, medical market

Navidea Has Jouned Forces with Maimonides Medical Centre Investigate Lymphoseek

Feb 6, 2013

Navidea Biopharmaceuticals has jouned forces with Maimonides Medical Centre to investigate Lymphoseek injections as a potential treatment for colorectal cancer. Dr. Danny Sherwinter, surgeon and the director of the Department of Minimally ...

Tags: Medical Centre, Biopharmaceuticals, clinical study

Navidea Has Entered Into an Agreement to License Alseres Parkinson's Disease Imaging Agent

Dec 18, 2012

Navidea Biopharmaceuticals has entered into an agreement to license Alseres Pharmaceuticals' Iodine-123 radiolabeled imaging agent, [123I]-E-IACFT Injection (CFT). The patented small molecule radiopharmaceutical imaging agent, which ...

Tags: Parkinson's disease, CFT, clinical technology

Navidea Biopharmaceuticals Reported Net Loss Attributable to Common Stockholders of$9.12m

Dec 4, 2012

Navidea Biopharmaceuticals has reported a net loss attributable to common stockholders of $9.12m, or $0.09 per share, for the third quarter ended 30 September 2012 compared to a net income attributable to common stockholders of $19.81m, or ...

Tags: Navidea Biopharmaceuticals, common stockholders, radiopharmaceutical

Navidea

Related Products